Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Curetis  /  Curetis 2019: er op of er onder

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel OpGen OTC:OPGN.Q, US68373L5057

  • 3,480 21 mei 2024 21:58
  • -0,380 (-9,85%) Dagrange 3,310 - 3,920
  • 61.925 Gem. (3M) 1,7M

Curetis 2019: er op of er onder

4.112 Posts
Pagina: «« 1 ... 149 150 151 152 153 ... 206 »» | Laatste | Omlaag ↓
  3. forum rang 10 DeZwarteRidder 6 november 2019 17:04
    Curetis voert omzet op

    Gepubliceerd op 18 sep 2019 om 08:19 | Views: 2.944

    Curetis 16:47
    0,49 +0,02 (+3,59%)

    AMSTERDAM (AFN) - Biotechnologiebedrijf Curetis heeft zijn omzet in de eerste helft van het jaar met een derde verhoogd. Het operationele verlies werd in dezelfde periode kleiner, zo bleek uit de uitgestelde halfjaarrapportage van de in Amsterdam genoteerde onderneming.

    Het Duitse bedrijf, dat onlangs bekendmaakte samen te gaan met de Amerikaanse branchegenoot OpGen, slaagde er dit jaar tot nu toe in stappen te zetten met het verder op de markt brengen van zijn diagnosesystemen in de VS. Ook werden stappen gezet met dochterbedrijf Ares.

    De omzet steeg met 35 procent tot bijna 1,1 miljoen euro. Het operationele verlies werd bijna 10 procent teruggebracht tot 10,3 miljoen. Eind juni had het bedrijf nog 7,8 miljoen euro in kas tegenover 10,3 miljoen eind december vorig jaar.

    Curetis maakte half augustus bekend zijn halfjaarcijfers uit te stellen. Daarvoor werd volgens de onderneming gekozen zodat de cijfers nog eens goed gecontroleerd kunnen worden in het kader van de nieuwe IFRS-regels. Begin september kondigde Curetis aan samen te willen gaan met zijn Amerikaanse branchegenoot OpGen.
  8. [verwijderd] 6 november 2019 17:47
    Ik begrijp de waarde van het aandeel momenteel.
    Totale waarde $ 24 miljoen (gecombineerd OpGen en Curetis).
    Curetis 72,5% is +/- $ 17,4 miljoen.
    Curetis heeft 25.623.129 aandelen uitgegeven.
    Per aandeel 17,4/25,623129 is +/- $ 0.68
    In euro's 0.68/ (110/111) = 0,612
    Koers ligt wat lager maar dat is begrijpelijk.
  11. [verwijderd] 6 november 2019 18:24
    Het fluteren van het aandeel in veelal range 0,47 -0,56 range is dus begrijpelijk.
    Totale waarde $ 24 miljoen (gecombineerd OpGen en Curetis).
    Curetis 72,5% is +/- $ 17,4 miljoen.
    Curetis heeft 25.623.129 aandelen uitgegeven.
    Per aandeel 17,4/25,623129 is +/- $ 0.68
    In euro's 0.68/ (100/111) = 0,612
    Koers ligt wat lager maar dat is begrijpelijk.
    Ik denk dat de koers tot de fusie rond is dominant in deze range zal vertoeven.
  13. [verwijderd] 6 november 2019 18:30
    quote:

    Go4profit schreef op 6 november 2019 18:24:

    Het fluteren van het aandeel in veelal range 1,47 -1,56 range is dus begrijpelijk.
    Totale waarde $ 24 miljoen (gecombineerd OpGen en Curetis).
    Curetis 72,5% is +/- $ 17,4 miljoen.
    Curetis heeft 25.623.129 aandelen uitgegeven.
    Per aandeel 17,4/25,623129 is +/- $ 0.68
    In euro's 0.68/ (100/111) = 0,612
    Koers ligt wat lager maar dat is begrijpelijk.
    Ik denk dat de koers tot de fusie rond is dominant in deze range zal vertoeven.
    Je denkt dus dat we tussen de 1.47 en 1.56 gaan komen of begrijp ik je rekensom niet?
  15. forum rang 4 Pitmans 6 november 2019 18:42
    quote:

    Go4profit schreef op 6 november 2019 18:24:

    Het fluteren van het aandeel in veelal range 0,47 -0,56 range is dus begrijpelijk.
    Totale waarde $ 24 miljoen (gecombineerd OpGen en Curetis).
    Curetis 72,5% is +/- $ 17,4 miljoen.
    Curetis heeft 25.623.129 aandelen uitgegeven.
    Per aandeel 17,4/25,623129 is +/- $ 0.68
    In euro's 0.68/ (100/111) = 0,612
    Koers ligt wat lager maar dat is begrijpelijk.
    Ik denk dat de koers tot de fusie rond is dominant in deze range zal vertoeven.
    We zijn weer een half uur verder, tijd om dezelde post nog een keer te plaatsen
  18. forum rang 10 DeZwarteRidder 6 november 2019 19:30
    Curetis and OpGen Enter Into Definitive Agreement to Combine Businesses
    September 04, 2019 06:55 ET | Source: OpGen, Inc.

    Combined company creates a commercial-stage, transatlantic diagnostics company focusing on data-driven solutions for molecular microbiology
    Combined company to be headquartered in Gaithersburg, MD, USA
    Transaction is supported by the boards of OpGen and Curetis
    Transaction subject to approval by both companies’ shareholders and debt financing providers
    Conference call scheduled for September 4, 2019, at 9:00 am Eastern / 3:00 pm Central European Time

    Elements of this announcement contain or may contain inside information within the meaning of Article 7(1) of the Market Abuse Regulation.

    GAITHERSBURG, Md. and AMSTERDAM, The Netherlands and HOLZGERLINGEN, Germany, Sept. 04, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, and Curetis N.V. (Euronext: CURE, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced the entry into a definitive agreement to combine the two companies’ businesses, subject to approval by both companies’ respective shareholders and Curetis’ debt financing providers. The transaction is structured as an acquisition by OpGen of Curetis GmbH, a wholly-owned subsidiary of Curetis which owns all of the Curetis Group business. The combination will create a transatlantic, U.S.-headquartered and Nasdaq-listed company with an innovative commercial-stage molecular diagnostics and bioinformatics franchise and a strong pipeline focusing on infectious diseases and antimicrobial resistance (AMR).

    Following the closing, the combined company's U.S. headquarters will be in Gaithersburg, MD, while the company’s European operations will be run from Holzgerlingen, Germany. Ares Genetics GmbH (“Ares Genetics”), a subsidiary of Curetis GmbH, will continue its bioinformatics and NGS service laboratory operations in Vienna, Austria.

    The combined companies will have a broad commercial-stage diagnostics portfolio of CE-IVD-marked and US-FDA cleared products and platforms, as well as a proprietary NGS-based and AI-powered technology and knowledgebase for the rapid molecular prediction of AMR. The initial two main focuses for the company will be (a) rapid diagnostics for lower respiratory infection and urinary tract infection and (b) bioinformatics and NGS services for AMR prediction by Ares Genetics as well as bioinformatics services based on the Acuitas Lighthouse® AMR knowledgebase by OpGen. Key elements of the combined company’s strategy include: continuing to gain regulatory clearances and approvals and establish a market position for proprietary molecular diagnostic tests and platforms, capitalize on unique technology platforms, leverage global commercial capabilities and partnerings, pursue development collaborations, and capitalize on the financial leverage and operational and research synergies to improve return on capital and achieve future profitability.

    “We are convinced that the combination of OpGen and Curetis will help maximize value for our stockholders and will result in an organization with a robust pipeline of molecular diagnostic and bioinformatics products, significant management experience, and proprietary assets for developing and commercializing novel data-driven solutions in infectious disease diagnostics,” said Evan Jones, Chairman and CEO of OpGen.

    “This transaction will allow Curetis to access U.S. capital markets, which we believe is essential to accelerate the development of our proprietary molecular diagnostic platforms and solutions for microbiology,” said Oliver Schacht, CEO of Curetis. Mr. Schacht continued, “It also strengthens our management team and financial position, allows us to leverage OpGen´s existing U.S. public company infrastructure, and adds complementary assets to our product development portfolio.”

    "We believe that this transaction has the potential to create substantial synergies and will enable the combined entity to further strengthen its molecular microbiology diagnostics pipeline and assets," said William Rhodes, Chairman of Curetis' Supervisory Board. "Our goal is to create a broader transatlantic business, allowing us to execute on a growth strategy in molecular microbiology based on cutting-edge innovation."

    The implementation agreement has been approved by both companies’ Boards of Directors. Curetis will seek approval from its shareholders at an extraordinary general meeting and OpGen will seek approval from its stockholders at a special meeting. It is expected that both meetings will be scheduled for the late fourth quarter of this year. Subject to receipt of shareholder approvals and satisfaction of other closing conditions, as detailed below, the transaction is expected to close by early 2020.

    Upon completion of the transaction, the combined company’s Board of Directors will be chaired by William Rhodes, currently the Chairman of the Curetis Supervisory Board, and will initially consist of four representatives named by Curetis and two by OpGen. Evan Jones, the current Chairman, President and Chief Executive Officer of OpGen, will join the combined company’s Board of Directors in a non-executive role. The senior management team of the combined company will consist of Oliver Schacht, Ph.D., currently the Chief Executive Officer of Curetis, as the combined company’s CEO, and Timothy C. Dec, currently the Chief Financial Officer of OpGen, as the CFO of the combined company, and additional representatives from the two companies.

    H.C. Wainwright & Co., LLC and Crosstree Capital LLC acted as financial advisors to Curetis and OpGen, respectively. Linklaters LLP and Ballard Spahr LLP acted as legal advisors to Curetis and OpGen, respectively.

  19. forum rang 10 DeZwarteRidder 6 november 2019 19:30
    Details of the Transaction

    Form of the Transaction

    Under the terms of the implementation agreement, OpGen proposes to acquire 100% of the shares of Curetis GmbH from Curetis N.V., thereby acquiring all of Curetis GmbH’s assets and liabilities, including the Curetis name. Curetis GmbH owns substantially all of the assets, liabilities and contractual obligations of the Curetis Group, including its subsidiaries Curetis USA Inc. and Ares Genetics GmbH. Upon Closing (as defined below), Curetis GmbH will be a wholly-owned subsidiary of OpGen.

    Post-Closing Ownership Allocations

    At the closing of the transaction (the “Closing”), Curetis N.V. will be entitled to receive 2,662,564 new shares of common stock of OpGen (less the number of shares to be reserved for issuance to current holders of options, phantom stock and convertible debt securities issued by Curetis N.V.), reflecting a valuation of the combined business of roughly $24 million.

    As of September 3, 2019, these 2,662,564 new shares would represent approximately 72.5% of the outstanding equity of OpGen (on a fully diluted basis), and current equity holders of OpGen (including option holders and warrant holders) would hold approximately 27.5% of the equity of OpGen (on a fully diluted basis). The respective equity holdings upon Closing will be subject to any dilutive issuance of securities by OpGen between the date hereof and the date of Closing.

    Subject to shareholder approval, Curetis intends to distribute to its shareholders, to the maximum extent permitted by law, the new OpGen shares it will receive at Closing in connection with the transaction.

    Stockholder Approvals

    As soon as reasonably practicable following and subject to availability of all required information including required financial statements, OpGen will file a registration statement on Form S-4, which will include a proxy statement for the OpGen stockholders (the “Form S-4”). OpGen expects to call a special meeting of its stockholders to be held as soon as practicable after the finalization and effectiveness of the Form S-4. Curetis expects to call an extraordinary general meeting of its shareholders on the same date as the OpGen special meeting.

    Conditions to Closing

    The Closing is subject to (i) the satisfaction of customary conditions to closing for a transaction of this type, including the absence of a material adverse event for either party, (ii) for each of OpGen and Curetis, appropriate approvals by their respective shareholders, (iii) for Curetis, consents from certain debt financing providers, (iv) the Form S-4 having been declared effective by the U.S. Securities and Exchange Commission, (v) the new shares of OpGen’s common stock to be issued (or reserved for issuance) in connection with the transaction having been approved for listing on Nasdaq and (vi) OpGen having secured additional funding prior to Closing.

    Conference Call Wednesday, September 4, at 9:00 am Eastern Time / 03:00 pm Central European Time

    OpGen and Curetis will jointly host a conference call today, September 4, 2019 at 9:00 am ET / 3 pm CET to discuss the planned combination and their businesses.

    For participating in the conference call, please access the presentation at: webcasts.eqs.com/curetis20190903/no-a...

    To access the call, please dial the following numbers:
4.112 Posts
Pagina: «« 1 ... 149 150 151 152 153 ... 206 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!